Validation of BMP8A fibrosis score to identify patients with metabolic dysfunction-associated steatohepatitis with advanced liver fibrosis

Abstract Liver fibrosis represents the main risk factor not only for liver-related but also for overall mortality in metabolic dysfunction-associated steatotic liver disease (MASLD) patients, being metabolic dysfunction-associated steatohepatitis (MASH) its more severe clinical form. We recently dev...

全面介紹

書目詳細資料

Principais autores:	Stephania C. Isaza, Carlos Ernesto Fernández-García, Diego Rojo, Paula Iruzubieta, Javier Ampuero, Rocío Aller, Raquel Vinuesa Campo, Laura Izquierdo-Sánchez, Esther Fuertes-Yebra, Patricia Marañón, Jesús M. Banales, Laura Pagés, Carolina Jiménez-González, Javier Rodríguez de Cía, Irene Olaizola, Judith Gómez-Camarero, Víctor Arroyo-Lopez, Manuel Romero-Gómez, Javier Crespo, Juan M. Pericàs, Carmelo García-Monzón, Águeda González-Rodríguez, on behalf of HEPAmet Registry
格式:	Artigo
語言:	Inglês
出版:	BMC 2025-11-01
叢編:	Biomarker Research
主題:	Advanced liver fibrosis MASLD MASH BMP8A BFS Non-invasive diagnosis
在線閱讀:	https://doi.org/10.1186/s40364-025-00862-3
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!